Could the human papillomavirus vaccination be cost-effective in males for the prevention of oropharyngeal cancer?

Wanrudee Isaranuwatchai, Donna M. Graham, Lillian L. Siu, Jeffrey S Hoch

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

Could the human papillomavirus (HPV) vaccination be cost-effective in males for the prevention of oropharyngeal squamous cell cancer (OPC)? It could be under certain conditions. Research on HPV vaccine has focused mainly on females. However, within the next decade, it is predicted that OPC will surpass cervical cancer as the most common HPV-related cancer, and it is postulated that HPV vaccination may alter the incidence of OPC. The purpose of this editorial is to comment on the potential cost-effectiveness of HPV vaccination in males for OPC prevention by addressing three elements payers often consider when making a decision to fund an intervention and to provide an overview of recent findings regarding the cost-effectiveness of HPV vaccine in males.

Original languageEnglish (US)
Pages (from-to)763-765
Number of pages3
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume14
Issue number6
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Keywords

  • Cost-effectiveness analysis
  • Economic evaluation
  • Human papillomavirus
  • Oropharyngeal cancer
  • Vaccine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy
  • Medicine(all)

Fingerprint Dive into the research topics of 'Could the human papillomavirus vaccination be cost-effective in males for the prevention of oropharyngeal cancer?'. Together they form a unique fingerprint.

Cite this